Gemcitabine plus cisplatin chemotherapy with concurrentpara-toluenesulfonamide local injection thera

Para-toluenesulfonamide (pTS)active ingredient beinoPTS, is a new anticancer drug applied through localintratumoral injection. The aim of this phase Il clinical triawas to investigate the response and toxicity of standardgemcitabine (GEM)plus cisplatin (CIS) chemotherapy withconcurrent intratumoral injection of PTS in peripherallyadvanced nonsmall cell lung cancer Patients received1250 mg/m2 of GEM on day 1, 8, and 75 mg/m2 of CISon day 1, every 21 days for four cycles. PTS was iniectedintratumorally through percutaneous injection undercomputed tomography guidance on days 5, 12 15 and18 of cycle 1, and repeated on days 5 and 12 of cycle 2if less 50% necrosis area was achieved after the first cycleaccording to computed tomography scan. Twelve (46.2)patients had metastatic disease, whereas 14 (53.8)patients had stage IllB disease. All 26 patients wereassessable for response. Overall response rate by

occurred in nine patients (34.6%), only one had grade 3vomiting. Grade 1-2 cough, local pain, and peripheraneurotoxocity developed in 12 (46.2) three (11.5)and five (19.2%) patients, respectively. There were notreatment-related deaths. GEM/CIS chemotherapy withconcurrent PTS local injection therapy is a welltoleratedmodality with potential activity in previously untreatedperipheral advanced nonsmall cell lung cancer patients.Anti-Cancer Drugs 00:000-000   2009 Wolters KluwerHealth   Lippincott Williams & Wilkins.

Anti-Cancer Drugs 2009,00:000-000

Kevwords: cisplatin, gemcitabine nonsmall cell lung cancer.para-toluenesulfonamide